The RIOX2 (RIBOXYLIN 2) antibody targets the RIOX2 protein, also known as MINA53 (MYC-induced nuclear antigen 53), a member of the JmjC-domain-containing histone demethylase family. Discovered as a MYC-responsive gene, RIOX2 is implicated in regulating ribosomal RNA (rRNA) processing and epigenetic modifications. It localizes to the nucleolus and plays roles in cell proliferation, differentiation, and tumorigenesis. Structurally, RIOX2 contains a conserved JmjC domain, enabling its hydroxylase activity, which influences histone H3K9 methylation and ribosomal biogenesis.
RIOX2 overexpression is observed in various cancers (e.g., colorectal, lung, and hepatocellular carcinomas), correlating with poor prognosis. Its oncogenic role involves promoting cell cycle progression, inhibiting apoptosis, and enhancing metastasis. The RIOX2 antibody is essential for detecting protein expression in tissues or cell lines via techniques like Western blotting, immunohistochemistry, or immunofluorescence. Researchers utilize it to explore RIOX2's functional mechanisms, its interaction with MYC signaling, and its potential as a therapeutic target. Commercial antibodies are typically validated for specificity using knockout cell lines or siRNA-mediated silencing. Ongoing studies focus on elucidating RIOX2's role in epigenetic regulation and cancer biology, aiming to develop inhibitors for clinical applications.